The Indian drugmaker initiated the recall for the 200 milligram dosage form of the drug on Dec. 20 after it failed to meet dissolution specifications. About 11,618 bottles of bupropion hydrochloride were pulled from shelves, according to the report.
The Food and Drug Administration classified the recall as class-III, meaning the products violate FDA labeling or manufacturing rules, but are unlikely to cause any adverse health reactions.
More articles on supply chain:
Shifting drug production back to US could raise prices: 5 takeaways
5 ways to prepare your supply chain for a disaster
Mayo Clinic physician: A stripped down FDA would be ‘chaotic’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.